Explore selected publications, evidence types, key findings, and registered studies with direct links to each primary record. This curated library is not a complete archive of the thousands of studies across the wider scientific literature.
52 publications
Showing records relevant to TB-500.
Key finding
In full-thickness rat wounds, thymosin beta-4 increased re-epithelialization by up to 61%, increased collagen deposition and angiogenesis, and accelerated wound contraction.
The Journal of investigative dermatology 1999
Related full-length Thymosin beta-4 animal evidence for TB-500. Relevant to TB-500
Key finding
Thymosin beta-4 and an actin-binding-domain peptide accelerated dermal repair in diabetic and aged mice, with greater collagen deposition, angiogenesis and wound closure.
Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society 2003
Related Thymosin beta-4 fragment animal evidence for TB-500. Relevant to TB-500
Key finding
This review links thymosin beta-4 to cell migration, angiogenesis, reduced inflammation and repair across dermal, corneal and cardiac injury models.
Trends in molecular medicine 2005
Related full-length Thymosin beta-4 repair review for TB-500. Relevant to TB-500
Key finding
This translational review summarizes thymosin beta-4's roles in cell migration, blood-vessel formation, inflammation control and tissue regeneration.
Expert opinion on biological therapy 2011
Related Thymosin beta-4 translational review for TB-500. Relevant to TB-500
Key finding
The review consolidates evidence that thymosin beta-4 supports cytoprotection, angiogenesis and tissue repair through actin regulation and multiple downstream pathways.
Annals of the New York Academy of Sciences 2010
Related Thymosin beta-4 mechanism review for TB-500. Relevant to TB-500
Key finding
The objective of this double-blind, placebo-controlled, dose-escalation study is to evaluate safety, tolerability, and enhancement on healing of thymosin beta-4 (Tbeta-4) administered topically in patients with venous ulcers.
Annals of the New York Academy of Sciences 2007
Direct or closely related TB-500 and thymosin beta-4 evidence. Relevant to TB-500
Key finding
This publication examines treatment of chronic nonhealing neurotrophic corneal epithelial defects with thymosin beta 4.
Archives of ophthalmology (Chicago, Ill. : 1960) 2010
Direct or closely related TB-500 and thymosin beta-4 evidence. Relevant to TB-500
Key finding
Thymosin beta 4 (T beta 4) is a 4.9 kDa polypeptide that interacts with G-actin and is thought to be an important mediator in cell proliferation, migration, and differentiation.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 1997
Direct or closely related TB-500 and thymosin beta-4 evidence. Relevant to TB-500
Key finding
These findings underscore the crucial role of rhTB4 in mitigating cardiac dysfunction in an ErbB2-dependent manner.
Cardiovascular research 2025
Direct or closely related Thymosin beta-4 evidence. Relevant to TB-500
Key finding
Chronic nonhealing cutaneous wounds are a worldwide problem with no agent able to promote healing.
Annals of the New York Academy of Sciences 2012
Direct or closely related TB-500 and thymosin beta-4 evidence. Relevant to TB-500
Key finding
Previously, thymosin beta 4 (Tbeta(4)) was found to promote wound healing in full thickness skin wounds and heptanol debrided corneas.
Experimental eye research 2002
Direct or closely related TB-500 and thymosin beta-4 evidence. Relevant to TB-500
Key finding
Synthetic thymosin beta 4 (Tbeta4) may have a potential use in promoting myocardial cell survival during acute myocardial infarction.
Annals of the New York Academy of Sciences 2010
Direct or closely related Thymosin beta-4 evidence. Relevant to TB-500
Key finding
The formulation TB-500 is suspected to be used as doping agent in sport.
Drug testing and analysis 2012
Direct or closely related TB-500 and thymosin beta-4 evidence. Relevant to TB-500
Key finding
At least 50% of the actin in resting human platelets is unpolymerized, and the bulk of this unpolymerized actin is complexed with a recently identified acidic, heat-stable 5-kDa peptide, named "Fx." Purified Fx binds stoichiometrically to muscle G-actin, forming a complex identifiable by nondenaturing polyacrylamide gel electrophoresis.
The Journal of biological chemistry 1991
Direct or closely related Thymosin beta-4 evidence. Relevant to TB-500
Key finding
A veterinary preparation known as TB-500 and containing a synthetic version of the naturally occurring peptide LKKTETQ has emerged.
Journal of chromatography. A 2012
Direct or closely related TB-500 and thymosin beta-4 evidence. Relevant to TB-500
Key finding
Our dream of defeating the processes of organ damage and aging remains a challenge scientists pursued for hundreds of years.
International immunopharmacology 2023
Direct or closely related Thymosin beta-4 evidence. Relevant to TB-500
Key finding
Thymosin beta 4 (Tβ4) has important applications in ocular repair and Phase 3 clinical trials using Tβ4 to treat dry eye and neurotrophic keratopathy are currently ongoing.
Expert opinion on biological therapy 2018
Direct or closely related TB-500 and thymosin beta-4 evidence. Relevant to TB-500
Key finding
Chronic ocular surface diseases such as dry eye, blepharitis, and neurotrophic keratopathies represent a significant and a growing therapeutic challenge.
Vitamins and hormones 2016
Direct or closely related Thymosin beta-4 evidence. Relevant to TB-500
This library supports source-led professional evaluation. Product-specific clinical and regulatory guidance provides the framework for interpreting the records in context.
Browse all products